Vertex Pharmaceuticals Inc (VRTX)

4,672.50
-87.21(-1.83%)
  • Volume:
    1,433
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    4,666.00 - 4,726.00
  • Type:Equity
  • Market:Mexico
  • ISIN:US92532F1003
  • S/N:92532F100

VRTX Overview

Prev. Close
4,759.71
Day's Range
4,666-4,726
Revenue
-
Open
4,720
52 wk Range
3,650-5,099.99
EPS
-
Volume
1,433
Market Cap
1.19T
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
664
P/E Ratio
-
Beta
-
1-Year Change
-1.63%
Shares Outstanding
254,251,938
Next Earnings Date
-
What is your sentiment on Vertex Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Vertex Pharmaceuticals Inc Company Profile

Employees
3400

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellNeutralBuyStrong Buy
Technical IndicatorsNeutralStrong SellStrong SellStrong BuyStrong Buy
SummarySellStrong SellSellStrong BuyStrong Buy
  • Keeps this stock, rotation from tech growth to value stock is coming this year, I expect VRTX will benefit from this.
    1
    • What a priceless tought. Safe money here in this actual cenario...
      0
  • this is a most unexpected though long awaited bump. glad i held
    0
    • finally, it's moving, I'm holding this one from more than a year
      0
      • it's so underpriced
        1
        • was there a stock split last 12 months?
          2
          • Nope?
            0
          • No
            0
        • was there a stock split last 12 months?
          1
          • this is almost half price from peak now
            0
            • this is almost half price from peak now
              0
              • Can’t wait for monday
                0
                • Great results 🥳
                  0
                  • another drop ...
                    0
                    • Will go up next week
                      1
                    • Not
                      0
                  • premarket +2, then market opens and it's slump... what happened ? does somebody know ?
                    0
                    • why has the stock crashed so much last 4 months?
                      0
                      • Inside this company is a disfunctional mess.
                        0
                    • undervalued buy buy
                      0
                      • Order.market reiterated its outperform rating on Vertex $VRTX. Go go go $VRTX
                        1
                    • stock moved 50 cents upon good ER,
                      1
                      • Good earnings & better outlook
                        1
                        • hi
                          0
                          • Hi
                            0
                        • i made a very conservative dcf and 208. this stock is undervalued
                          0
                          • Just VRTX
                            0
                            • today we will recieve a massive punch. hope it resist 175
                              10
                              • I have previously said my opinion on this company. options for the next week are selling at 195-20 for a total of over 0.5 billion. I don't think it's a coincidence. high probability of leakage of inside information long before the decision. Also suggestive of price manipulation. in short, the SEC needs to take a close look at all this
                                2
                                • Shares of Vertex Pharmaceuticals tumbled 13% in after-hour trading after the company announced it would end its development of VX-864, a liver-disease drug. Vertex said in a press release that “the magnitude of treatment effect observed in this study is unlikely to translate into substantial clinical benefit.”
                                  0
                                  • Just need 230 but waiting for 7 months already..
                                    0
                                    • good news !
                                      0
                                      • Of the companies whose drugs have recently been approved by the FDA, Biogen, which is larger than Vertex, has seen tremendous growth. Several factors contributed to this, such as low PE, a brand new drug, perhaps the first for Alzheimer's disease. We also have a company, Novo Nordisk, their obesity cure was adopted a few days ago. The company is 3 times the size of Vertex and their PE is 30, therefore this increase was only 15%
                                        0
                                      • What?? Moderna is a recent pharmaceutical company supported by Trump, just have covid vacinne.. You want to compare with vertex?
                                        0
                                      • OK so how do you explain Moderna price comparing with aztrazeneca or Pfizer?
                                        0
                                    • Does anybody know what the ********is going on here?
                                      0
                                      • No but i’m waiting for EMA valutation
                                        0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.